The Precision-First™ Technological Platform

The foundation of Endpoint Health’s operational model is its proprietary artificial intelligence and machine learning platform. The company has established clinical partnerships with over 60 premier hospital systems worldwide (including institutions like the Cleveland Clinic and Vanderbilt University). These partnerships power a massive biological data ecosystem that aggregates deep molecular, genetic, and clinical profiles from critically and chronically ill patients.

The technological platform functions through a specific three-step loop:

1. Biomarker and Subpopulation Discovery

The AI platform analyzes clinical datasets to uncover unique biological signals and distinct patient subgroups (subphenotypes) within broadly defined diseases. It identifies high-responder patient populations that exhibit specific molecular pathways driving their immune dysregulation.

2. De-Risked Asset Selection (Precision In-Licensing)

Rather than focusing solely on traditional, molecule-first drug discovery which carries high failure rates, Endpoint Health uses its platform to identify existing therapeutic assets—often those with proven safety profiles but mixed results in general, unstratified clinical trials. By matching these assets to the specific patient subpopulations identified by the AI, the company dramatically increases the probability of clinical trial success.

3. Companion Diagnostic Integration

For every therapeutic program advanced, Endpoint Health builds a companion diagnostic (a therapy-guiding test). These rapid diagnostic tools are engineered for deployment in active clinical environments, allowing healthcare providers to identify a patient's specific immune state in real time and match them with the corresponding targeted therapy.

Pipeline and Product Offerings

Endpoint Health is actively building a proprietary pipeline centered on precision immunology, focusing on both acute critical care emergencies and chronic autoimmune conditions.

1. Critical Care Programs (Acute Immunology)

• Antithrombin III (AT-III) for Sepsis: Developed in a major global collaboration and licensing agreement with Grifols (a leading producer of plasma-derived medicines). Sepsis occurs when the body's immune response to an infection becomes dysregulated, often leading to multi-organ failure. Endpoint Health is utilizing its AI platform and a proprietary diagnostic test to identify specific subphenotypes of septic patients who are most likely to experience therapeutic benefits from AT-III. Under this model, Grifols acts as the exclusive supplier of the plasma protein, while Endpoint Health manages the clinical development, regulatory approval, and worldwide commercialization.
• Acute Respiratory Distress Syndrome (ARDS) Precision Therapeutics: The company utilizes its computational models to predict patient outcomes and response patterns to common treatment strategies in ARDS. By identifying underlying inflammatory signatures, Endpoint Health aims to deploy targeted interventional molecules to halt runaway pulmonary inflammation.

2. Chronic Inflammatory and Autoimmune Programs

• EP004 (First-in-Class Anti-TF Monoclonal Antibody): Acquired through the strategic purchase of Iconic Therapeutics, EP004 (formerly ICON-4) is a first-in-class monoclonal antibody targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling. Tissue factor is a known driver of inflammation, cell migration, and clotting across a wide spectrum of Immune-Mediated Inflammatory Diseases (IMIDs). EP004 is uniquely designed to reduce pro-inflammatory cytokines and chemokines by selectively inhibiting TF-dependent intracellular signaling, without interfering with the normal blood-coagulation functions of the TF pathway. Endpoint Health utilizes its precision AI platform to stratify potential responders across multiple multi-billion dollar indications, including:
  • Ulcerative Colitis
  • Crohn’s Disease
  • Systemic Lupus Erythematosus (Lupus)
  • Specialized Vasculitides

3. Therapy-Guiding Diagnostics (Services & Solutions)

While not sold as standalone consumer products, Endpoint Health’s companion diagnostics represent a core component of its service framework for hospital networks. These diagnostic panels are designed to interface seamlessly with critical care workflows, providing clinicians with rapid, actionable molecular data to guide bedside decision-making and patient stratification during clinical trials.

Target Markets and Strategic Positioning

Endpoint Health targets major therapeutic areas that collectively account for an enormous burden on global healthcare infrastructure. Chronic immune-mediated diseases affect roughly 5% to 7% of the world's population, while acute immune-driven critical illnesses impact nearly 14%.

By specializing in diseases where traditional therapies face high failure rates—such as Inflammatory Bowel Disease (IBD), where nearly half of patients do not adequately respond to standard biological treatments—Endpoint Health provides value to multiple healthcare stakeholders:

• Biopharma Partners: Allowing legacy pharmaceutical companies to unlock the commercial value of their portfolios by identifying the exact patient groups where a drug will succeed.
• Healthcare Systems and Clinicians: Supplying tools that reduce hospital mortality rates, optimize the utilization of high-cost intensive care unit (ICU) resources, and replace trial-and-error medicine.
• Investors and Sovereign Funds: Operating a highly capitalized model backed by prominent life science and institutional investors (including Mayfield, Humboldt Fund, AME Cloud Ventures, and the Global Health Investment Corporation), designed to bring lower-risk, highly effective therapeutics to market.